WS #10990
Evommune's EVO756 failed to meet primary endpoint in chronic urticaria, causing stock to tumble.
Evommune Phase 2b Trial Miss
Evommune's EVO756 failed to meet primary endpoint in chronic urticaria, causing stock to tumble.
Evommune's EVO756 failed to meet primary endpoint in chronic urticaria, causing stock to tumble.
Evommune's EVO756 failed to meet primary endpoint in chronic urticaria, causing stock to tumble.